Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

HeartFlow

Explore full profile

A non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease

San Francisco, United StatesFounded 2007Biotech & Life Sciences
Valuation $3.99B Market cap · 2026
Revenue $230M Latest reported FY

About HeartFlow

HeartFlow is a health technology startup that operates in the cardiovascular care market. The company has developed a non-invasive cardiac test that provides detailed visualization of a patient's coronary arteries. This innovative technology assists physicians in creating more effective treatment plans for their patients, thereby making cardiovascular care safer and easier.

The company's primary clients are physicians and healthcare providers who are looking for safer, more efficient ways to diagnose and treat heart disease. HeartFlow's technology eliminates the need for invasive procedures, reducing both the risk to patients and the cost to healthcare providers.

HeartFlow's business model is based on the sale of its proprietary technology. The company's HeartFlow Analysis, which includes the FFRCT Analysis, RoadMap Analysis, Plaque Analysis, and HeartFlow Planner, has received FDA Clearance in the United States and is commercially available in the United States and the United Kingdom. It is also approved in Japan and Canada.

The company generates revenue by selling its technology to healthcare providers. It also likely earns income from ongoing service and maintenance contracts, as well as from updates and improvements to its technology.

In summary, HeartFlow is a health tech startup that has developed a non-invasive cardiac test to assist physicians in diagnosing and treating heart disease. The company operates in the cardiovascular care market and generates revenue from the sale of its technology and related services.

Source: Dealroom company data

At a glance

Status
Listed
Founded
2007
Headquarters
San Francisco, United States
Listing
IPO 2025
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Investors

14 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed3 investors entered at this stage

Series A1 investor entered at this stage

Series B and later10 investors entered at this stage

Employees mapped 856 incl. 13 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 15 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
9 countries with
team presence
🇺🇸 United States95.6%
🇬🇧 United Kingdom2.4%
🇯🇵 Japan0.6%
🇨🇦 Canada0.5%
🇩🇪 Germany0.1%
Top 5 of 9 shown
Web traffic by country
71K monthly visits
across markets
🇺🇸 United States81.3%
🇦🇺 Australia3.9%
🇯🇵 Japan3.2%
🇬🇧 United Kingdom2.7%
🇮🇳 India1.8%
Top 5 markets shown

Patents

Estimated portfolio value
$229M

88 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about HeartFlow on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See HeartFlow on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.